Gambella Alessandro, Falco Enrico Costantino, Benazzo Giacomo, Osella-Abate Simona, Senetta Rebecca, Castellano Isabella, Bertero Luca, Cassoni Paola
Pathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Molecular Pathology Unit, "Città della Salute e della Scienza di Torino" University Hospital, Turin, Italy.
Front Med (Lausanne). 2022 Feb 14;9:837876. doi: 10.3389/fmed.2022.837876. eCollection 2022.
The management of endoscopically resected pT1 colorectal cancer (CRC) relies on nodal metastasis risk estimation based on the assessment of specific histopathological features. Avoiding the overtreatment of metastasis-free patients represents a crucial unmet clinical need. By analyzing a consecutive series of 207 pT1 CRCs treated with colectomy and lymphadenectomy, this study aimed to develop a novel clinicopathological score to improve pT1 CRC metastasis prediction. First, we established the clinicopathological profile of metastatic cases: lymphovascular invasion (OR: 23.8; CI: 5.12-110.9) and high-grade tumor budding (OR: 5.21; CI: 1.60-16.8) correlated with an increased risk of nodal metastasis, while age at diagnosis >65 years (OR: 0.26; CI: 0.09-0.71) and high tumor-infiltrating lymphocytes (OR: 0.19; CI: 0.06-0.59) showed a protective effect. Combining these features, we built a five-tier risk score that, applied to our series, identified cases with a higher risk (score ≥ 2) of nodal metastasis (OR: 7.7; CI: 2.4-24.4). Notably, a score of 0 was only assigned to cases with no metastases (13/13 cases) and all the score 4 samples (2/2 cases) showed nodal metastases. In conclusion, we developed an effectively combined score to assess pT1 CRC nodal metastasis risk. We believe that its adoption within a multidisciplinary pT1 unit could improve patients' clinical management and limit surgical overtreatment.
内镜下切除的pT1期结直肠癌(CRC)的管理依赖于基于特定组织病理学特征评估的淋巴结转移风险估计。避免对无转移患者进行过度治疗是一项关键的未满足的临床需求。通过分析连续207例接受结肠切除术和淋巴结清扫术治疗的pT1期CRC,本研究旨在开发一种新的临床病理评分系统,以改善pT1期CRC转移预测。首先,我们确定了转移病例的临床病理特征:淋巴管浸润(OR:23.8;CI:5.12 - 110.9)和高级别肿瘤芽生(OR:5.21;CI:1.60 - 16.8)与淋巴结转移风险增加相关,而诊断时年龄>65岁(OR:0.26;CI:0.09 - 0.71)和高肿瘤浸润淋巴细胞(OR:0.19;CI:0.06 - 0.59)显示出保护作用。结合这些特征,我们构建了一个五级风险评分系统,应用于我们的系列病例,识别出淋巴结转移风险较高(评分≥2)的病例(OR:7.7;CI:2.4 - 24.4)。值得注意的是,评分为0仅分配给无转移的病例(13/13例),所有评分为4的样本(2/2例)均显示有淋巴结转移。总之,我们开发了一种有效组合的评分系统来评估pT1期CRC淋巴结转移风险。我们相信,在多学科pT1单元中采用该评分系统可以改善患者的临床管理并限制手术过度治疗。